Price matters. That's true whether we're talking about cars, houses, laptops, or anything else -- including stocks.

Three Motley Fool contributors had price in mind when choosing Axsome Therapeutics (NASDAQ: AXSM), CRISPR Therapeutics (NASDAQ: CRSP), and Pfizer (NYSE: PFE) as top picks for investors right now. Here's why they think buying these dirt-cheap stocks could be a brilliant move.

Prosper Junior Bakiny (Axsome Therapeutics): It's not easy to value relatively small, unprofitable biotechs with few products. Though that description fits Axsome Therapeutics, there are plenty of clues that, in my view, make the company's market cap of $3.7 billion seem too low compared to its growth potential. Axsome Therapeutics has a rich, late-stage pipeline that should help transform its lineup in the next couple of years.

Continue reading

Source Fool.com